This article first appeared on GuruFocus .
Release Date: May 12, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Lineage Cell Therapeutics Inc ( LCTX ) successfully expanded its Alloscope manufacturing platform, leading to the launch of the CORE1 corneal endothelial cell transplant program.
-
The company met its first internal milestone with the ILT1 manufacturing initiative, showcasing progress in its manufacturing capabilities.
-
Lineage Cell Therapeutics Inc ( LCTX ) established a new scientific advisory board, attracting an established cell therapy executive as its founding member.
-
The OPERGEN program showed promising long-term vision gains in patients with dry AMD, with data indicating potential disease-modifying effects.
-
The company has a strong cash position of $53.4 million, expected to support operations into Q2 of 2028, with potential additional funding from existing warrants and milestone payments.
Negative Points
-
The OPERGEN program's future remains uncertain as the company awaits a decision on advancing into a multicenter controlled trial.
-
Lineage Cell Therapeutics Inc ( LCTX ) reported a net loss of $4.8 million for the first quarter of 2026, an increase from the previous year.
-
The company faces challenges in scaling up the production of islet cells for type 1 diabetes, with significant hurdles in achieving commercial viability.
-
Enrollment in the OPC1 dose study is challenging, particularly for subacute patients, due to the need for tragic incidents to occur near clinical sites.
-
The company is still in the early stages of developing its CORE1 and ILT1 programs, with significant work needed before reaching clinical trials.
Q & A Highlights
Q: On OPERGEN, your understanding of it being characterized as disease-modifying relates to what data was presented at the recent Foundation Fighting Blindness Summit. How do you think of the photoreceptor recovery and some of the stratifying web coverage data that you have integrated as part of the GALET trial? A: With regard to disease modification, we do not have access to the data in the ongoing GALET study. However, the opening of 11 sites after initially having six is a clear indicator of planning for a larger campaign. The recent presentation included language about potentially modifying disease, which is a positive change. Our insights regarding bleb coverage and photoreceptor recovery come from our own Phase I/EBITDA and other companies' data, not from the ongoing GALET study.
Q: On the corneal endothelial cell program, what's the internal criteria you may have met here, and what sort of work is underway preclinically? What should we watch for as you proceed with manufacturing and IND filing? A: For the corneal program, we focus on achieving a high-quality manufacturing process that is reproducible and doesn't need changes during development. This approach reduces risk, especially in indications with a cadaver-sourced precedent for efficacy. We invite scrutiny on the reproducibility, scalability, and potency assays of our material, as these are integral to a product's survival.
Q: Can you provide thoughts on the competitive data in the RPE cell space and geographic atrophy space, particularly regarding Astellas and ISTEM's updates? A: Astellas' data update is an important clearing event for us. We haven't seen much information about their manufacturing, delivery, or safety, and the data is limited. We feel comforted that we remain in a leading position. Regarding complement inhibitors, they show a small treatment effect, but there's no evidence of impact on visual function. RPE transplants, however, have shown to increase patients' vision.
Q: Regarding the dose study of OPC-1, are there any updates on the CIRM grant application? A: We reapplied for a CIRM grant in January, and a decision is expected later this summer. If we receive the grant, it would be beneficial, but not receiving it won't materially impact the program. We are moving forward with the dose study and plan to introduce our internally-made cells into the ongoing trial.
Q: On the ILT1 program, what are the risks when differentiating baseline pluripotent cells into ILT cells, and how might this impact scale-up? A: Differentiating pluripotent cells into specific cell types like islets is challenging. While we can expand RPE cells post-differentiation, islet cells don't expand once differentiated. The focus is on pre-differentiation, but risks exist at every step. We've had success in GMP environments and are confident in our team's ability. The approach is stepwise and risk-reducing, with go-no-go decision points to manage investment prudently.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
